Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | PPIB | P23284 | 7/20 | 0.36 |
| ▸ | PPID | Q08752 | 9/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | PPIG | Q13427 | 5/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832176 | 0.79 | EPHX1 (0.46) | EPHX1PPIBPPIDRAB9APOLB | |
| SCHEMBL15832160 | 0.75 | PPIB (0.44) | PPIBPPIDPOLBPPIG | |
| SCHEMBL15832187 | 0.69 | PPID (0.42) | EPHX1PPIBPPIDRAB9ASMN1; SMN2 | |
| SCHEMBL19882160 | 0.68 | HDAC6 (0.45) | EPHX1PPIDRAB9APOLBSMN1; SMN2 | |
| SCHEMBL15832178 | 0.66 | PPIB (0.77) | PPIBPPIDSMN1; SMN2PPIGPPIA | |
| SCHEMBL15832143 | 0.65 | PPID (0.47) | EPHX1PPIBPPIDPOLBITGB3 | |
| SCHEMBL5946809 | 0.65 | PDK1 (0.44) | — | |
| SCHEMBL3085761 | 0.64 | HDAC6 (0.60) | EPHX1RAB9APOLBSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL3857669 | 0.63 | HDAC6 (0.59) | EPHX1RAB9APOLBSMN1; SMN2NPC1 | |
| SCHEMBL14619100 | 0.63 | PPIB (0.43) | EPHX1PPIBPPIDITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | EPHX1 645/4885PPIB 51/4885PPID 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.